DeCure for Pulmonary large cell neuroendocrine carcinoma
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for pulmonary large cell neuroendocrine carcinoma — screening already-approved drugs against its 47-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePulmonary large cell neuroendocrine carcinoma maps to a 47-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pulmonary large cell neuroendocrine carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Cbl proto-oncogene B (CBLB) — CBLB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4-methyl-1,2,4-triazol-3-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8QTG · 1.419 Å · ligand 3-[3-[3-methyl-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-5-(trifluoromethyl)-1~{H}-pyridin-2-one (WUQ). Experimental structure, not a prediction.
What the evidence adds up to
Pulmonary large cell neuroendocrine carcinoma is a rare and aggressive malignancy strongly linked to smoking, accounting for 2.4% to 3.1% of lung cancer surgical specimens. It is notoriously difficult to diagnose and treat, and its biological and clinical characteristics are similar to small cell lung cancer despite being classified as non-small cell lung cancer. Treatment for the disease remains controversial.
A 2024 study of 38 patients with large cell neuroendocrine carcinoma of the lung reported a mean Ki-67 proliferation index of 65.8% (±20.8). When patients were grouped by a Ki-67 cut-off of 65%, median overall survival was 22.2 months (95% CI 21.7-22.7) for those with Ki-67 below 65% and 20.3 months (95% CI 4.5-36.2) for those with Ki-67 at or above 65%. The difference was not statistically significant (p=0.351). Overall survival was numerically lower in patients aged 65 years and over, those with right-sided tumours, those metastatic at diagnosis, those who did not receive chemotherapy, those who did not undergo curative surgery, and those with chronic diseases, but none of these differences reached statistical significance (p>0.05).
Recent molecular data show that large cell neuroendocrine carcinoma is a biologically heterogeneous group of tumours with morphologic and genomic diversity that straddles small cell and non-small cell lung carcinomas, and in a minority of cases atypical carcinoids. Genomic sequencing has identified molecular subtypes and potential diagnostic and prognostic markers, but the low incidence and small sample sizes of available studies have limited progress.
What is still missing are larger, adequately powered studies to establish the prognostic importance of clinical and histopathological characteristics such as Ki-67 index, and to resolve the ongoing controversy over optimal treatment strategies. No randomised controlled trial data are available to guide therapy, and no validated molecular stratification has been translated into clinical practice.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Translational Lung Cancer Research · 2020 · 57 citations · open access
Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis
AbstractPulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive malignancy that is strongly linked to smoking and notoriously difficult to diagnose and treat. Recent molecular data reveal that it represents a biologically heterogeneous group of tumors, characterized by morphologic and genomic diversity that straddles small cell and non-small cell lung carcinomas (NSCLCs), and in a minority of cases atypical carcinoids. This review provides an update on recent molecular and clinical developments in LCNEC with the main focus on practical approach to pathologic diagnosis using illustrative examples of the main differential diagnostic considerations.
Revista da Associação Médica Brasileira · 2024 · 3 citations · open access
Effect of Ki-67 proliferation index on survival in large cell neuroendocrine carcinoma of the lung
AbstractOBJECTIVE: Large cell neuroendocrine carcinoma of the lung is a rare type of lung cancer. There is a limited number of studies on clinical and histopathological characteristics that are effective in survival. The aim of this study was to investigate the relationship between histopathological and clinical characteristics, mainly Ki-67 proliferation index, and survival in patients diagnosed with large cell neuroendocrine carcinoma of the lung. METHODS: The data of 38 patients followed up with the diagnosis of large cell neuroendocrine carcinoma of the lung were evaluated. The mean Ki-67 value was determined to be 65.8% (±20.8). The patients' clinical characteristics and survival times were compared according to the cut-off value determined for Ki-67 index. RESULTS: When median overall survival times were compared, it was seen that overall survival was numerically lower in patients aged 65 years and over, in tumors located on the right side, in cases who were in the metastatic stage at diagnosis, whose Ki-67 index was 65% and above, who did not receive chemotherapy, who did not undergo curative surgery, and in patients with chronic diseases (p>0.05). In the Kaplan-Meier analysis, the median overall survival was determined to be 22.2 months (95%CI 21.7-22.7) in the patients with Ki-67<65%, while it was found to be 20.3 months (95%CI 4.5-36.2) in the patients with Ki-67≥65% (p=0.351). CONCLUSION: Our study identified subgroups with decreased survival in large cell neuroendocrine carcinoma of lung patients. Studies including a larger number of patients are needed to identify the prognostic importance of these clinical and histopathological characteristics.
Progress in comprehensive treatment of pulmonary large cell neuroendocrine carcinoma
AbstractLarge cell neuroendocrine carcinoma is not very common, and it has a high degree of malignancy and invasion, outcome is also poor. Even LCLC is defined as non-small cell lung cancer, its biological and clinical characteristics, prognostic factors are similar to small cell lung cancer. The treatment for LCLC is still controversial. The research progress on comprehensive treatment of lung large cell neuroendocrine carcinoma was reviewed.
Key words:
Lung large cell neuroendocrine carcinoma/combined modality therapy; Progression
[Advances in Molecular Biomarker for Pulmonary Large Cell Neuroendocrine Carcinoma].
AbstractPulmonary large cell neuroendocrine carcinoma (LCNEC) is a pathological subtype of lung neuroendocrine cancer, which accounts for 2.4%-3.1% in surgical specimens of lung cancer. It is characterized by high invasiveness and poor prognosis, and highly correlated with smoking. There are few relevant studies due to the low incidence and small sample size. Therefore, it is relatively difficult to diagnosis and treatment in clinical practice. In this review, we described molecular subtype, diagnostic and prognostic-related markers about large cell neuroendocrine carcinoma of lung based on the recent progress in genomic sequencing and molecular markers, to find the direction for the next research. .
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
